MGC Pharmaceuticals Ltd
ASX:MXC
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
MGC Pharmaceuticals Ltd
ASX:MXC
|
18.2m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
930.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
233.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.2B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
MGC Pharmaceuticals Ltd
Glance View
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for MGC Pharmaceuticals Ltd is 21.9%, which is below its 3-year median of 29.9%.
Over the last 3 years, MGC Pharmaceuticals Ltd’s Gross Margin has decreased from 25% to 21.9%. During this period, it reached a low of 21.9% on Jan 1, 2024 and a high of 50.3% on Dec 31, 2022.
